This is because mRNA levels of SIRT2 are up-regulated in cells from patients with high-risk AML, where this sirtuin promotes NADPH production by deacetylating the enzyme glucose-6-phosphate dehydrogenase (G6PD) or the phosphorylation of AKT kinase [6,7]. This evidence concerns the gene G6PD and acute myeloid leukemia.